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the 16p13.11 duplication),  NDEL1 (including the overlapping 
 MYH10  gene) and  CIT . Our findings provide further evidence 
for involvement of  DISC1 and its interaction partners in neu-
ropsychiatric disorders and also for a role of structural vari-
ants in the aetiology of these devastating diseases. 
 © 2015 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 Schizophrenia, schizoaffective disorder and bipolar 
disorder are phenotypically and genetically overlapping 
severe psychiatric disorders, cumulatively affecting ap-
proximately 3% of the population worldwide  [1–4] . Like 
many other common diseases, they are complex and mul-
tifactorial, with contributions from multiple susceptibil-
ity genes and epigenetic, stochastic, and environmental 
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 Abstract 
 Robust statistical, genetic and functional evidence supports 
a role for  DISC1 in the aetiology of major mental illness. Fur-
thermore, many of its protein-binding partners show evi-
dence for involvement in the pathophysiology of a range of 
neurodevelopmental and psychiatric disorders. Copy num-
ber variants (CNVs) are suspected to play an important caus-
al role in these disorders. In this study, CNV analysis of  DISC1 
and its binding partners  PAFAH1B1 ,  NDE1 ,  NDEL1 ,  FEZ1 , 
 MAP1A ,  CIT and  PDE4B in Scottish and Northern Swedish 
population-based samples was carried out using multiplex 
amplicon quantification. Here, we report the finding of rare 
CNVs in  DISC1 ,  NDE1 (together with adjacent genes within 
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factors  [5] . Family, twin and adoption studies have shown 
that genetic factors play a major role in the development 
of schizophrenia  [4] , and also in mood disorders  [6] 
which have estimated heritability values between 60 and 
85%. The search for susceptibility genes has however 
been challenging, especially in mood disorders, where it 
has been hampered by clinical and genetic heterogeneity. 
 It has been shown in schizophrenia research that there 
is a spectrum of risk alleles from common, low penetrant 
forms such as single nucleotide polymorphisms (SNPs) 
identified from large genome-wide association studies 
(GWAS) to rarer, highly penetrant forms such as copy 
number variants (CNVs; segments of DNA with duplica-
tions and deletions) found at increased frequency in dis-
ease from a number of genome-wide CNV studies  [7, 8] . 
Whilst the majority of mental illness at the population 
and individual level is likely to be caused by a combina-
tion of many risk alleles, there may be some forms of ill-
ness which are due to rarer variants that are themselves 
sufficient to cause illness in those individuals or families 
expressing them. Such variants can be biologically infor-
mative because they can be used to develop molecular, 
cellular and animal models of psychosis to help unravel 
the underlying disease mechanisms.
 One such rare variant, first discovered in a Scottish cy-
togenetic study of juvenile delinquency, has been a bal-
anced translocation from chromosome 11 into the long 
arm of chromosome 1. It was found to segregate with 
schizophrenia, bipolar disorder and major depression in 
other family members with major mental illness being 
found in roughly half of family members carrying the 
translocation (log of the odds ratio = 7.1)  [9, 10] . Ten 
years later, the previously unknown gene Disrupted-In-
Schizophrenia 1  (DISC1) on chromosome 1 was identi-
fied as disrupted by the translocation  [11] . Since then, 
 DISC1 has attracted much attention, not only being as-
sociated with schizophrenia but also predisposing indi-
viduals to a wide range of major mental disorders, includ-
ing bipolar disorder, major depression and autism spec-
trum disorders (ASD), in different populations  [12–29] . 
In addition, association has been detected between  DISC1 
alleles or haplotypes and measurable traits related to 
schizophrenia and bipolar disorder, including working 
memory  [30–32] , cognition  [22, 25] , reduced grey matter 
volume, brain activation  [33] and abnormalities in hip-
pocampal structure and function  [21, 34] . By condition-
ing a previous GWAS study on  DISC1 , 8 genes  (LCT, 
CCDC141, TTN, CXCL3, KIAA1128, MED13L, MIR620 
and  TMC07) have been identified as associating with psy-
chosis proneness, and these molecules predominantly 
link to the DISC1 pathway  [35] . Through genetics, cell 
biology, animal modelling and neuroimaging, the DISC1 
pathway is emerging as a pivotal mediator of quantitative 
and pathological brain dysfunction  [36] . 
 DISC1 expression in the brain is particularly high in 
the hippocampus during neurogenesis and remains high 
in the adult dentate gyrus, olfactory bulb and limbic re-
gions  [37, 38] , and it appears that  DISC1 regulates impor-
tant developmental processes such as neuronal migra-
tion, integration  [39] , synapse formation and neuronal 
stem cell maturation  [38, 40–42] . DISC1 is thus critical 
for neurodevelopment and normal adult neuronal func-
tion. In addition, transgenic or mutant mice with im-
paired  DISC1 function show brain morphological chang-
es, deficits in neural circuits, working memory impair-
ment and behavioural traits related to schizophrenia and 
also bipolar disorder  [43–49] . 
 DISC1 acts as a large scaffold protein interacting with 
multiple protein partners  [50–52] , several of which have 
been shown to be important for cytoskeleton stability and 
modulation, intracellular transport, cAMP signalling, 
synaptic signal transduction and synaptic plasticity  [53] . 
These DISC1 interactors are independent risk factors for 
major mental illness  [54] , making the DISC1 protein in-
teraction network a potential target for future therapeutic 
intervention. Synaptic deficits and transcriptional dys-
regulation have recently been shown in induced pluripo-
tent stem cell-derived forebrain neurons from patients 
with mutant DISC1  [55] . The so-called modelled ‘DISC1 
interactome’ has been proposed to consist of 127 proteins 
and 158 interactions  [52] . Sixty-seven of these proteins 
are direct DISC1 interactors and interestingly many of 
these DISC1 interactors also interact with one another, 
suggesting their involvement in common pathways, al-
though the functional role of the majority of these poten-
tial interactors in neuronal development has yet to be 
shown in vivo  [54] . Of these DISC1 interactors, we se-
lected 7 that have a likely functional relation with psychi-
atric disorders based on evidence from the literature, 
namely platelet-activating factor acetylhydrolase 1b reg-
ulatory subunit 1 gene  (PAFAH1B1) , Nuclear distribu-
tion factor E-homolog 1 gene (NDE1) , NDE-like 1 gene 
 (NDEL1) , Fasciculation and Elongation Protein Zeta-1 
gene  (FEZ1) , Microtubule-associated Protein 1A gene 
 (MAP1A) , CITRON gene  (CIT) and  cAMP-hydrolysing 
enzyme phosphodiesterase 4 gene (PDE4B) . Altogether, 
a substantial body of genetic and biological evidence sup-
ports a role for DISC1 and the 7 described interacting 
partners (summarised in  table 1 ) in the development of 
psychiatric disorders.
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 Table 1.  Evidence supporting a role for the seven DISC1 interacting partners in the development of psychiatric disorders
DISC1 interactor Expression and proposed function Disease associations and animal models
PAFAH1B1 Encodes protein LIS1 which localizes to the centrosome 
and is a component of the microtubule-based dynein 
motor complex involved in neurogenesis and neuronal 
migration
Mutations in PAFAH1B1 cause the neuronal migration 
disorder lissencephaly [68 – 70]
Disruption of PAFAH1B1 in animal models show
cerebral cortex malformations [71, 72]
NDE1 and
NDEL1
NDE1 and NDEL1 localize to the centrosome and are 
components of the microtubule-based dynein motor 
complex
NDE1 is a cytoskeletal protein that participates in 
essential neurodevelopmental processes, including 
neuronal precursor proliferation and differentiation, 
neuronal migration, and neurite outgrowth [73]
Phosphorylated NDE1 is present at the postsynaptic 
density, in proximal axons, within the nucleus, and at
the centrosome where it becomes substantially enriched 
during mitosis. Mutation of the NDE1 phosphorylation 
site (T131) inhibits neurite outgrowth [74]
Abundance of the NDEL1-DISC1 complex is highest 
during neuronal migration in the developing cortex [75]
NDE1 and NDEL1 may compete with each other for 
DISC1 binding [76]
NDEL1 expression is reduced in brain tissue of patients 
with schizophrenia [39]
Mouse studies suggest that NDE1-mediated 
heterochromatin replication is critical for neuronal 
differentiation, and loss of NDE1 function may lead to 
genomic neurological disorders [77]
Familial mutations in NDE1 cause severe failure of 
neurogenesis and cortical lamination 
(microlissencephaly) [78, 79]
NDE1 associated with psychosis proneness in a large 
Finnish birth cohort upon re-analysis of GWAS linkage 
data conditioned on a DISC1-associating risk haplotype 
[35]
Linkage found between NDE1 and schizophrenia in 
families with individuals carrying DISC1 risk alleles
[73] – interaction between NDE1 or NDEL1 genotypes 
and DISC1 genotypes are associated with schizophrenia 
[76]
NDE1 CNVs associate with a range of phenotypically 
different neurodevelopmental disorders including 
intellectual disability [80], ASD [81], attention deficit 
hyperactivity disorder [82], epilepsy [83] and 
schizophrenia [67, 80]
FEZ1 Anchors microtubules near the cell membrane and plays 
a role in axon bundling and axonal transport
FEZ1 expression pattern closely resembles that of DISC1 
and the DISC1/FEZ1 complex appears to be involved in 
neurite outgrowth [41]
FEZ1 interacts with DISC1 to synergistically regulate 
dendritic growth of newborn neurons in the adult mouse 
hippocampus [84]
FEZ1 mRNA expression is reduced in schizophrenia [85]
Association between FEZ1 and schizophrenia was found 
in a Japanese cohort [86]
FEZ1 knockout mice exhibit abnormal brain 
architecture, hyperactivity and enhanced responsiveness 
to psycho-stimulants [87]
Epistatic interaction between FEZ1 and DISC1-
associated with risk of schizophrenia [84]
MAP1A Controls microtubule polymerization and stabilization 
and is required for axon and dendrite development [88, 
89]
Binds with post-synaptic density protein PSD-95 [90,
91] – essential for the correct membrane localization of 
multiple neurotransmitter receptors/synaptic proteins
CIT CITRON (encoded by CIT) binds with post-synaptic 
density protein PSD-95 [90]
CIT has been shown to be associated with BP disorder 
[92]
PDE4B Plays a role in intracellular signal transduction by 
degrading cAMP
Dissociation of PDE4B from DISC1 inactivates its 
enzymatic activity
PDE4B interacts with the LIS1/NDEL1/NDE1/DISC1 
dynein motor complex at the centrosome and may play
a role in regulating its structure and function [53]
Mainly expressed in the cortex, hippocampus and 
striatum, brain regions implicated in memory and 
cognition
PDE4B was found to be disrupted by a translocation 
breakpoint in 2 related individuals with psychosis [93]
Association has been found between SNPs in PDE4B and 
schizophrenia [94 – 96]
Specific PDE4 inhibitor rolipram shown to facilitate 
long-term memory and to have antidepressant and 
antipsychotic activity [97, 98]
PDE4B knockout mice show antidepressant-like 
behaviour and a proliferation of neuronal cells in the 
hippocampus [99, 100]
Two DISC1 missense mutations in mice, which result in 
depressed and schizophrenic phenotypes, are located 
within specific PDE4B binding sites [44]
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 In GWAS performed for schizophrenia and bipolar 
disorder, no SNPs in  DISC1 or in any of its binding part-
ners were found among the most significant results. Only 
a few SNPs with moderate significance were found, but 
there has been no consistency between different studies 
(catalogue of published GWAS: http://www.genome.
gov/26525384)  [56] . Current GWAS effectively capture 
the majority of common variants but not rare variants 
and structural variations, such as genomic rearrange-
ments or CNVs, in the European population. This type of 
variation may contribute significantly to the inter-indi-
vidual variation in susceptibility to diseases  [57–60] . Ge-
nome-wide CNV studies have shown that rare CNVs are 
found at an increased frequency in patients with schizo-
phrenia compared to control individuals  [56, 61–67] , 
constituting risk factors with low prevalence but high 
penetrance. Therefore, in this study we test the hypothesis 
that CNVs disrupting or encompassing  DISC1 or any of 
the 7 binding partners influence susceptibility to schizo-
phrenia and bipolar disorder in the Scottish and Swedish 
populations and to major depressive disorder and intel-
lectual disability (ID) in the Scottish population samples. 
Hereto, we used a technique named multiplex amplicon 
quantification (MAQ), which allows high-resolution 
CNV detection (kilobase range) at specific genomic re-
gions, and thus covers small CNVs that are missed by 
many current genome-wide CNV detection platforms. 
 Subjects and Methods 
 Subjects 
 Scotland  
 The Scottish sample used in this study consists of a cohort of 
1,293 unrelated cases [647 with schizophrenia, 213 with bipolar af-
fective disorder, 192 with major depressive disorder and 241 with 
ID (ID, ID + schizophrenia and ID + ‘comorbid’] and 352 unre-
lated controls. The study was approved by the Multi-Centre Re-
search Ethics Committee for Scotland, and patients gave written 
informed consent for the collection of DNA samples for use in ge-
netic studies. The sample comprised Caucasian individuals con-
tacted through the inpatient and outpatient services of hospitals in 
North East (nearest city: Aberdeen) and South East (nearest city: 
Edinburgh) Scotland. For the South East Scotland samples, a diag-
nosis of schizophrenia was based on information from an interview 
with the patient using the Schedule for Affective Disorders and 
Schizophrenia-Lifetime version (SADS-L) supplemented by case 
note review and frequently by information from medical staff, rela-
tives and caregivers. Patients with bipolar affective disorder and 
unipolar depression were also identified at the Royal Edinburgh 
Hospital and associated hospitals, and final diagnoses, based on 
DSM-IV-TR criteria  [101] , were reached by consensus between 2 
trained psychiatrists and where possible using the Operational Cri-
teria Checklist for Psychotic Illness (OPCRIT)  [102] . Patients diag-
nosed with ID were over 18 years of age and recruited through the 
Learning Disability Services of South East Scotland. To be in this 
service, all patients were assessed to have an IQ <70. Within the 
National Health Service in the UK, psychiatrists are involved in the 
management of these patients regardless of whether or not they 
have a mental illness. We did not routinely reassess IQ in this study 
but relied on case note records as patients in the Learning Disabil-
ity Services have previously had IQ assessments by clinical psy-
chologists. Only ID patients with an IQ between 50 and 70 were 
included in this study. IQ assessment used Wechsler Intelligence 
Scale for Children (WISC) or Wechsler Adult Intelligence Scale 
(WAIS; most patients were part of the Learning Disabilities service 
since childhood). Most patients gave consent to take part in the 
study; however, if incapable of giving fully informed consent, a wel-
fare guardian or nearest relative was approached to also give con-
sent. Initial contact was through the responsible psychiatrist. Some 
patients were being treated for schizophrenia and major depression 
and some had no history of mental illness. Diagnoses according to 
DSM-IV criteria were reached using the semi-structured interview 
Psychiatric Assessment Schedule for Adults with a Developmental 
Disability (PAS-ADD 10) involving the patient and a key infor-
mant. Additional clinical information was obtained from hospital 
case note review. The Social Communication Questionnaire-Life-
time version (SCQ-L) provided a screen for autism, and high-
scoring individuals were followed up using the Autism Diagnostic 
Instrument-Revised (ADI-R). Initial diagnoses were confirmed 
through consultation between the relevant specialist clinician in-
volved and one of the research team members who was also a spe-
cialist in the psychiatry of ID (the late Prof. Walter Muir). Ethni-
cally matched controls from the same region were recruited through 
the South of Scotland Blood Transfusion Service and from hospital 
staff. All controls were not directly screened to exclude those with 
a personal or family history of psychiatric illness; however, the 
Blood Transfusion Service does not accept blood donations from 
subjects taking regular medication or with a history of major illness. 
Of the North East Scotland samples, all participants self-identified 
as born in the British Isles (95% in Scotland), diagnosis was con-
firmed with the OPCRIT symptom checklist  [102] , and all cases 
met the DSM-IV and International Classification of Diseases 10th 
Edition (ICD-10) criteria for schizophrenia. Detailed medical and 
psychiatric histories were collected, and a clinical interview using 
Structured Clinical Interview for DSM-IV (SCID) was also per-
formed on schizophrenia cases. Control samples were volunteers 
recruited through general practices in North East Scotland. Prac-
tice lists were screened for potentially suitable volunteers by age 
and sex and by exclusion of subjects with major mental illness or 
use of neuroleptic medication. Volunteers who replied to a written 
invitation were interviewed using a short questionnaire to exclude 
major mental illness in themselves and first-degree relatives.
 Sweden  
 All participants were Caucasians and originated from a geo-
graphically isolated population living in the County of Västerbot-
ten in Northern Sweden. Two large samples were used in this study 
from the Swedish population. One sample consists of 909 unre-
lated patients (410 schizophrenia, 120 schizoaffective disorder, 314 
bipolar affective disorder) and 512 unrelated control individuals. 
The other sample comprises 152 related patients and 227 of their 
first-degree relatives, all members of a large 14-generation pedi-
gree from Västerbotten County ( table 2 ). 
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 The unrelated patients were identified through the in-patient 
hospital registers in the region, and the ascertainment was carried 
out from 1992 to 2005. Diagnostic evaluation was performed by 
trained research nurses and research psychiatrists using register 
data, data from medical records, multiple informants, and, when 
deemed necessary and feasible, semi-structured interviews were 
used including MINI (Mini-International Neuropsychiatric Inter-
view)  [103] , DIGS (The Diagnostic Interview for Genetic Studies) 
 [104] , FIGS (The Family Interview for Genetic Studies)  [105] and 
SCAN (The Schedules for Clinical Assessment in Neuropsychia-
try)  [106] . The diagnoses were defined according to the DSM-IV 
criteria, and patients were included only if full consensus was 
reached by 2 research psychiatrists. To date, the patients have been 
followed-up for 3–13 years, giving ample opportunities for diag-
nostic validation and phenotypic characterization. 
 The 512 unrelated Swedish control individuals were recruited 
from the Betula study sample of 4,360 individuals representative 
of the general population of the region, described in detail else-
where  [107] . A prerequisite for inclusion in the Betula study was 
the ability to comply with a test battery consisting of a health ex-
amination, blood sample testing, interviews and self-rating scales 
about somatic and mental health, and an extensive examination of 
memory functions. For 9 Swedish control individuals carrying a 
CNV, in-depth clinical evaluation showed no signs of lifetime psy-
chiatric disorders. The 152 probands of the nuclear families were 
initially identified through hospital registers, and the diagnostic 
work-up was similar to the procedure described for the unrelated 
cases. A detailed description of the pedigree has been previously 
published  [108] . For the purpose of this study, we were not depen-
dent on a final DSM-IV diagnosis (ongoing assessment) of all 227 
first-degree relatives. Lifetime psychiatric disorders were evaluat-
ed in 13 first-degree relatives using a semi-structured interview 
based on the DIGS and FIGS. In these 13 individuals, 6 were CNV 
carriers and 7 were not but were a first-degree relative of a proband 
with a CNV. Of the 6 with a CNV, 3 had bipolar affective disorder 
and 3 were unaffected. Out of the 7 non-CNV carriers, 1 had bipo-
lar disorder, 1 had schizoaffective disorder and 5 were unaffected 
( table 2 ). All subjects participated after giving written informed 
consent, and the study was approved by the regional Medical Eth-
ics Committees of the Universities of Umeå and Antwerp. We also 
analysed the 30 HapMap trios of the CEU (Utah residents with 
ancestry from Northern and Western Europe) population. DNA 
of these 90 individuals was obtained from the Coriell Institute 
(Camden, N.J., USA). 
 Table 2. Prevalence of CNVs in the Scottish and Swedish unrelated patient and control groups
Group DISC1 NDE1 NDEL1  CIT Total
Del, 
count 
(%)
Total 
Dup, 
count 
(%)
Total 
CNVs, 
count 
(%)
Del Dup Del Dup Del Dup  Del Dup
SCZ (Sc) 1/647 2/647 1/647 2/647 0/647 0/647 0/647 1/647 2 (0.31) 5 (0.77) 7 (1.08)
SCZ (Sw) 0/410 7/410 0/410 0/410 0/410 1/410 0/410 0/410 0 8 (1.95) 8 (1.95)
Total SCZ 1/1,057 9/1,057 1/1,057 2/1,057 0/1,057 1/1,057 0/1,057 1/1,057 2 (0.19) 13 (1.23) 15 (1.42)
Total SA (Sw) 0/120 0/120 0/120 1/120 0/120 0/120 0/120 0/120 0 0 0
BPD (Sc) 0/213 0/213 0/213 0/213 0/213 0/213 0/213 0/213 0 0 0
BPD (Sw) 0/314 6/314 0/314 0/314 0/314 0/314 0/314 0/314 0 6 (1.91) 6 (1.91)
Total BPD 0/527 6/527 0/527 0/527 0/527 0/527 0/527 0/527 0 6 (1.14) 6 (1.14)
Total MDD (Sc) 0/192 0/192 0/192 0/192 0/192 0/192 0/192 0/192 0 0 0
Total ID (Sc) 0/72 2/72 0/72 1/72 0/72 0/72 0/72 0/72 0 3 (4.17) 3 (4.17)
ID + SCZ (Sc) 0/92 0/92 0/92 1/92 0/92 0/92 0/92 0/92 0 1 (1.08) 1 (1.08)
ID + SCZ (Sw) 0/24 0/24 0/24 0/24 0/24 0/24 0/24 0/24 0 0 0
Total ID + SCZ 0/116 0/116 0/116 1/116 0/116 0/116 0/116 0/116 0 1 (0.86) 1 (0.86)
ID + comorbid (Sc) 0/77 0/77 0/77 1/77 0/77 0/77 0/77 0/77 0 1 (1.30) 1 (1.30)
ID + comorbid (Sw) 0/19 0/19 0/19 0/19 0/19 0/19 0/19 0/19 0 0 0
Total ID + comorbid 0/96 0/96 0/96 1/96 0/96 0/96 0/96 0/96 0 1 (1.04) 1 (1.04)
Control (Sc) 1/352 1/352 0/352 0/352 0/352 0/352 0/352 0/352 1 (0.28) 1 (0.28) 2 (0.57)
Control (Sw) 0/512 6/512 0/512 3/512 0/512 0/512 0/512 0/512 0 9 (1.76) 9 (1.76)
Total control 1/864 7/864 0/864 3/864 0/864 0/864 0/864 0/864 1 (0.16) 10 (1.16) 11 (1.27)
 Of the 8 gene regions screened, CNVs (duplications and deletions) were found in DISC1, NDE1, NDEL1 and CIT regions. No CNVs 
were found in PAFAH1B1, FEZ1, MAP1A or PDE4B in this study. SCZ = Schizophrenia; SA = schizoaffective disorder; BPD = bipolar 
disorder; MDD = major depressive disorder; Sc = Scottish; Sw = Swedish. Note: total ID + comorbid (Sc) – diagnoses with ID include 
BPD (n = 32), MDD (n = 26), autism (n = 17), Asperger’s (n = 1) and Klinefelter’s syndrome (n = 1); total ID + comorbid (Sw) – diagnoses 
with ID include schizoaffective disorder-bipolar type (n = 11), schizoaffective disorder-depressive type (n = 3), BPD (n = 2) and psychotic 
disorder not otherwise specified (n = 3). Shaded rows represent total values for Scottish and Swedish populations combined.
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 Multiplex Amplicon Quantification 
 Genomic DNA was extracted from peripheral blood using 
standard methods. To explore the 8 genes for CNVs, we used MAQ 
 [109, 110] . It consists of a multiplex PCR amplification of several 
fluorescently labelled target and reference amplicons, followed by 
fragment analysis on an ABI 3730 DNA analyzer (Applied Biosys-
tems). The comparison of normalised peak areas between patient 
and control individuals results in a dosage quotient (DQ) of the 
target amplicon. Seventy-nine target amplicons and 21 reference 
amplicons were amplified in three MAQ assays (online suppl. table 
SI; see www.karger.com/doi/10.1159/000438788 for all online
suppl. material). These assays are available on request from Prof. 
Del-Favero (jurgen.delfavero   @   molgen-vib.ua.be). The MAQ re-
actions were performed on 20-ng genomic DNA. DQs were calcu-
lated using an in-house developed MAQ software package (MAQ-
S; http://www.vibgeneticservicefacility.be/MAQ.htm). A DQ be-
tween 1.3 and 1.7 was considered indicative of a heterozygous du-
plication, a DQ between 0.3 and 0.7 indicative of a heterozygous 
deletion.
 Allelic Quantification 
 To confirm the findings of the MAQ analysis in the Northern 
Swedish population samples, we used allelic quantification by ge-
notyping SNPs in and around the duplicated amplicons using the 
Sequenom MassARRAY iPLEX Gold system (Sequenom, Germa-
ny). Individuals heterozygous for an SNP in a duplicated region 
show an allele ratio of 2: 1 (relative allele frequencies 0.667: 0.333) 
instead of the 1: 1 ratio (relative allele frequencies 0.5: 0.5) in a nor-
mal diploid genome. Relative quantification assays are run with 
the Typer Analyzer program (Typer 4.0, Sequenom) using Allelo-
typing mode. SNPs with the highest possible heterozygosity were 
selected from HapMap (www.hapmap.org) and genotyped in the 
individuals showing a duplication with MAQ. Primers for PCR 
amplification and extension primers (online suppl. table SII) were 
designed using the Assay Design 3.1 program (Sequenom). Geno-
typing of the SNPs was carried out following the protocol provid-
ed by Sequenom. Analysis and scoring were performed using the 
program Typer 4.0 (Sequenom). 
 The primer extension products of each allele are not always 
equally represented, so the expected relative allele frequencies 
when a duplication is present were calculated based on the mean 
relative frequency of allele A (f A ) and the mean relative frequency 
of allele B (f B ) obtained from analysis of individuals without a 
duplication in that specific region. Expected relative frequencies 
in a duplicated region would be (2f A /f B )/[1 + (2f A /f B )] and 1 – 
(2f A /f B )/[1 + (2f A /f B )] for duplication of the A allele or (f A /2f B )/[1 
+ (f A /2f B )] and (f A /2f B )/[1 + (f A /2f B )] for duplication of the B al-
lele.
 Chromosomal Microarray 
 For several of the Scottish samples, CNVs initially found by 
MAQ assay were confirmed by microarray analysis using a Cyto-
Scan 750K Array (Affymetrix UK Ltd.). Microarray analysis was 
also used to genotype other family members. The test DNA was 
referenced against a normal control dataset using the Affymetrix 
Chromosome Analysis Suite (ChAS) and ArrayLIMs. Further de-
tails of the array designs are available at affymetrix.com. 
 Results 
 MAQ Analysis 
 We explored  DISC1,  PAFAH1B1 ,  NDE1 ,  NDEL1 , 
 FEZ1 ,  MAP1A ,  CIT and PDE4B for whole or partial gene 
deletions or duplications in the Scottish and Northern 
Swedish samples. In the unrelated Scottish population-
based sample set, we screened 647 patients with a diagno-
sis of schizophrenia, 213 patients with bipolar disorder, 
192 patients with major depressive disorder, 72 patients 
with ID, 92 patients with ID and comorbid schizophrenia, 
77 patients with ID and a comorbid other psychiatric di-
agnosis including: 32 with bipolar affective disorder, 26 
with major depressive disorder, 17 with autism, 1 with 
Asperger’s syndrome and 1 with Klinefelter’s syndrome. 
The analysis also included screening 352 unrelated con-
trol individuals from the Scottish population ( table  2 ). 
The unrelated Swedish population-based samples includ-
ed 410 patients with a diagnosis of schizophrenia, 120 pa-
tients with schizoaffective disorder, 314 patients with bi-
polar disorder, 24 with ID and comorbid schizophrenia, 
and 19 with ID plus another comorbid psychiatric diag-
nosis including: 11 with schizoaffective disorder bipolar 
type, 3 with schizoaffective disorder depressive type, 2 
with bipolar affective disorder and 2 with psychotic dis-
order not otherwise specified ( table 2 ). This Swedish pop-
ulation-based sample analysis included screening 512 un-
related control individuals. Within the Swedish sample 
analysis, we also screened 152 related probands from a 
large pedigree as well as 227 first-degree relatives of these 
patients from an isolated Northern Swedish population 
( table 3 ). Ninety Swedish HapMap CEU individuals were 
also analysed in this study. We used the accurate high-
throughput MAQ method to detect whole or partial gene 
deletions or duplications, quantitatively amplifying sev-
eral target amplicons per gene ( fig. 1 ; online suppl. table 
SI). Fifty-seven target amplicons in and around the 8 
genes (‘amp’,  fig. 1 ) and 21 reference amplicons were an-
alysed in a first screen (online suppl. table SI). 
 DISC1 Copy Number Variants 
 In both the Scottish and Swedish unrelated samples, 
we detected CNVs in  DISC1 ( table 2 ). In the Scottish sam-
ples, we detected one affected individual with a deletion 
of at least 48 kb with a minimal region of 229,904,902–
229,952,723 (coordinates based on UCSC build 36) en-
coding intron 3 and 3 alternate exons of  DISC1  (chromo-
some 1q42.2). This particular deletion was found only in 
this one Scottish male patient with a diagnosis of schizo-
phrenia (1/647 = 0.15% in Scottish schizophrenia samples 
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or 1/1,057 = 0.09% combining both Scottish and Swedish 
schizophrenia samples) and was not found in any other 
of the Scottish or Swedish affected samples or in any of 
the Scottish or Swedish controls ( table 2 ). We found an 
unaffected Scottish individual who had a large deletion of 
at least 192 kb encoding the  TSNAX and the  TSNAX-
DISC1 boundary region. However, the deletion in this 
control individual spans from 229,622,813 to 229,814,916, 
which is further upstream from the start of the  DISC1  de-
letion found in the patient with schizophrenia ( table 4 ).
 In contrast to  DISC1 deletions,  DISC1 duplications 
were found to be more abundant in both the Scottish and 
Swedish population-based samples. Duplications of exon 
1 of  DISC1 were found in 5 individuals in the Scottish 
samples: in 2 patients with schizophrenia (2/647; 0.93%), 
2 patients with ID (2/72; 2.78%) and in 1 control sample 
(1/352; 0.28%). In the unrelated Swedish population-
based samples ( table 2 ), duplications in  DISC1 were found 
in 7 patients with schizophrenia (7/410; 1.7%), 5 with bi-
polar type 1 disorder and 1 with bipolar type 2 disorder 
(6/314; 1.9%) and 6 control individuals (6/512; 1.2%). In 
the related Swedish samples ( table 3 ), a  DISC1 duplica-
tion was detected in 2 patients with schizophrenia (2/27; 
7.4%), 3 with bipolar type 1, 2 with bipolar type 2 and 1 
with bipolar not otherwise specified patient (6/102; 5.8%) 
and in 3 unaffected relatives. On further analysis of the 
pedigrees of the nuclear families, the CNV did not segre-
gate with psychiatric disease in these Swedish samples: for 
the affected carriers as well as for the unaffected carriers, 
both affected and unaffected non-carrying first-degree 
relatives were found. An extra 22 target amplicons in this 
genomic region were subsequently analysed for fine map-
ping of the samples (‘newamp’,  fig. 1 ; online suppl. table 
SI). The duplication in  DISC1 in the Swedish samples has 
a maximum size of 107.4 kb and a minimum size of 98.8 
kb and encompasses the first exon of  DISC1 ( fig. 1 ). The 
 DISC1 duplication in the Scottish samples also encom-
passes the first exon of DISC1 and has a maximum size of 
52 kb and a minimum size of 1.9 kb ( table 4 ). In the Da-
tabase of Genomic Variants (DGV; http://dgv.tcag.cag, 
update October 2014), 5 CNVs are reported at this ge-
nomic location: variation 3334, variation 48275, variation 
48276, variation 30458 and variation 2350. Variations 
30458 and 2350 ( fig.  1 ) were detected in two HapMap 
CEU individuals, NA11830 (mother) and NA10856 (her 
son)  [111, 112] . We analysed the 90 HapMap CEU indi-
viduals with MAQ and allelic quantification assays and 
also detected the  DISC1 duplication in NA11830 and 
 Table 3. Prevalence of CNVs in related probands and first-degree relatives of the pedigree from the County of Västerbotten in Northern 
Sweden
Group Diagnosis n (M:F) First-degree 
relatives, n
Nuclear
families, n
Mean age
at onset,
years
Carriers of a duplication in:
DISC1, n % NDE1, n % NDEL1, n %
Related
probands
(152 in total)
SCZ 27 (18:9) 26 11 23.2 ± 6.6 2 (7.41) 0 0
SCZ + ID 2 (1:1) 3 2 28.5 ± 3.5 0 0 0
SCA 21 (13:8) 23 9 21.6 ± 7.9 0 1 (4.76) 0
SCA + ID 1 (0:1) 0 0 15 0 0 0
BPD1 49 (22:27) 73 35 28.2 ± 14.0 2 (4.08) 0 0
BPD1 + ID + autism 1 (0:1) 2 1 23 0 0 0
BPD2 49 (17:32) 95 37 30.5 ± 16.8 1 (2.04) 0 0
BPD2 + autism 1 (1:0) 3 1 20 0 0 0
BPD NOS 1 (0:1) 1 1 42 0 0 0
First-degree 
relativesa
(227 in total)
Total sample 227 (85:142) n.a. 98 n.a. 6 (2.64) 0 0
BPD1 2 (0:2) n.a. n.a. 25.5 ± 4.9 1 0 0
BPD2 1 (0:1) n.a. n.a. 14 1 0 0
BPD NOS 1 (0:1) n.a. n.a. 65 1 0 0
SCA (bipolar type) 1 (0:1) n.a. n.a. 14 0 0 0
Unaffected 8 (4:4) n.a. n.a. n.a. 3 0 0
Duplications were found only in DISC1, NDE1 and NDEL1. SCZ = Schizophrenia; SCA = schizoaffective disorder; BPD = bipolar 
disorder; NOS = not otherwise specified; n.a. = not applicable. a Diagnostic information is shown in 13 out of 227 first-degree relatives; 
6 carrying a CNV; 7 not carrying a CNV but are first-degree relatives of a proband with a CNV. Of the 6 with a CNV, 3 had BPD and 3 
were unaffected. Out of the 7 non-CNV carriers, 1 had BPD, 1 had SCA and 5 were unaffected.
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a
 1 
(For legend see next page.)
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NA10856, suggesting that these ‘three’ duplications are in 
fact one recurrent duplication. With a frequency of about 
1.5%, this duplication is a common variant in the North-
ern Swedish population. This might be a result of genetic 
drift in an isolated population, but the duplication may 
be a common variant in the general (Caucasian/Europe-
an) population, supported by its detection in 2 (related) 
HapMap CEU individuals. In the Northern Swedish pop-
ulation-based sample, the partial  DISC1 duplication is 
not associated with schizophrenia (χ 2 p value = 0.70), bi-
polar disorder (χ 2 p value = 0.44) or with both disorders 
together (χ 2 p value = 0.53). In addition, in the nuclear 
families, both affected and unaffected duplication carri-
ers were found with both affected and unaffected first-
degree relatives not carrying the duplication. So the par-
tial  DISC1 duplication is most likely not related to the 
disease phenotypes under study. Interestingly, in one 
Northern Swedish schizophrenia patient, 4 copies of the 
 DISC1 CNV were found (4 copies in total, i.e. 2 normal 
copies and 2 additional). DNA from the parents was not 
available for typing. It is possible that the extra copy pres-
ent in this patient does disturb DISC1 expression or pro-
tein function. Another interesting observation is that
the duplication also covers a novel processed transcript 
(OTTHUMT00000095276, Vega gene ID RP11-17H4.2, 
 fig.  1 ). This ‘gene’ has no open reading frame, and the 
 Fig. 1. Location of the quantitatively typed 
MAQ amplicons and SNPs with reference 
to the investigated and other known genes 
and to structural variants in the Database 
of Genomic Variants. Duplications are 
drawn in green, deletions in red and CNVs 
with unknown direction in orange colour. 
 a Detected duplications in 3 genes:  DISC1 , 
 NDE1 and  NDEL1 . The minimum size is 
indicated with a thick bar, the maximal size 
with a thin bar and undefined boundaries 
are indicated with arrows.  b Other genom-
ic regions investigated included  CIT ,
 PAFAH1B ,  FEZ1 and  PDE4B . The figure 
was made by adding custom tracks to the 
UCSC Genome Browser (http://genome.
ucsc.edu/cgi-bin/hgGateway). 
b
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function of the RNA transcript is yet unknown, but it 
might be implicated in the regulation of expression of (a) 
protein coding gene(s). Four functional copies of this 
DNA sequence might lead to a disturbingly elevated level 
of this non-coding RNA and interfere with its normal 
regulatory function. 
 NDE1 Copy Number Variants 
 CNVs were detected in  NDE1 in both the Scottish and 
Swedish sample sets ( table 2 ). A deletion in  NDE1 was 
detected by MAQ assay in one Scottish patient with a di-
agnosis of schizophrenia (1/647; 0.15%) and was not 
found in any other samples analysed in this study. With-
in the Scottish samples, we also found  NDE1 duplications 
in 5 patient samples but in no Scottish controls ( tables 2 
and  4 ). Two of the Scottish patients with  NDE1 duplica-
tions have a diagnosis of schizophrenia (Sc11034 and 
Sc6638), one has a diagnosis of ID and schizophrenia 
(Sc7292), one has a diagnosis of ID alone (Sc7474) and 
one patient Sc7615 has diagnoses of ID, autism and 
schizophrenia ( table 4 ). The  NDE1 duplications in 2 of 
the patients (Sc7292 and Sc7615) were also independent-
ly confirmed from GWAS, as they had been included in 
that analysis. Blood samples were subsequently obtained 
from the parents and all 4 siblings of Sc7615 and screened 
by microarray analysis using the Affymetrix CytoScan 
750K array. This shows a single copy gain of the short arm 
of chromosome 16 at band p13.11. The duplication is ap-
proximately 1.65 Mb in size spanning 14,892,975–
16,544,033 (NCBI Build 37). This 16p13.11 duplication 
was found to be maternally inherited and also present in 
two other siblings of Sc7615, one of whom has a history 
of psychosis ( fig. 2 ). The mother of Sc7615 has a strong 
family history of schizophrenia and affective disorders. In 
the Swedish population sample, the duplication was de-
tected in 1 patient with a diagnosis of schizoaffective dis-
order, bipolar type (1/120; 0.83%) and 3 control individu-
als (3/512; 0.59%) from the population-based sample, and 
in 1 patient with schizoaffective disorder, bipolar type 
from the related patients and relatives sample set ( ta-
ble 3 ). Fisher’s exact test for these Swedish case-control 
studies results in non-significant p values of 0.27, 0.13 
and 0.33, respectively. However, we believe that statistical 
analysis of the results of individual regions is not appro-
priate given how rare these CNVs are. In order to gener-
ate adequate statistical power, we would have to screen far 
larger sample sets than what was available. For these 
Swedish patients, no first-degree relative samples were 
available for testing, so segregation could not be verified. 
The duplication has a minimum size of 262 kb and en-
compasses  NDE1 and other genes; the exact 3 ′ and 5 ′ 
boundaries are undefined ( fig. 1 ). 
 NDEL1 Copy Number Variants 
 A duplication in  NDEL1 was found in 1 patient with a 
diagnosis of schizophrenia in the Swedish samples (1/410; 
0.24%) but not found in any Scottish samples or in any 
Scottish or Swedish control individuals. It encompasses 
the whole gene and has a minimum size of 141.3 kb 
( fig. 1 ). The 5 ′ boundary is undefined; at the 3 ′ side, the 
duplication maximally extends 85 kb past exon 9. 
 Table 4. Details on the individual CNV carriers that were identified in the Scottish samples
ID CNV/
cytoband
Minimal region Size,
kb
Genes Diagnosis Ori-
gin
Sex AAS/
AAO
Additional information
Sc11052 Dup 1q42.2 229,828,419 – 229,830,272 1.9 exon 1 DISC1 SCZ Sc M 36/28
Sc7401 Del 1q42.2 229,904,902 – 229,952,723 48 intron 3 and 3 alternate exons DISC1 SCZ Sc M 24/23
Sc11532 Dup 1q42.2 229,814,616 – 229,845,359 30 exon 1 DISC1 SCZ Sc M 34/19
Sc7473 Dup 1q42.2 229,828,419 – 229,830,272 1.9 exon 1 DISC1 ID Sc F 76/16 mild ID
Sc7473 Dup 1q42.2 229,814,616 – 229,845,359 30 exon 1 DISC1 ID Sc F 76/16 two DISC1 duplications were 
detected in this patient
Sc11986 Dup 1q42.2 229,793,461 – 229,845,359 52 exon 1 DISC1 control Sc F 59/–
Sc11293 Del 1q42.2 229,622,813 – 229,814,916 192 TSNAX/TSNAX-DISC1 control Sc M 53/–
Sc11120 Del 16p13.11 15,654,809 – 15,723,967 69 middle NDE1/end MYH11 overlap SCZ Sc M 30/17
Sc11034 Dup 16p13.11 15,654,809 – 15,723,967 69 middle NDE1/end MYH11 overlap SCZ Sc M 49/14
Sc6638 Dup 16p13.11 15,654,809 – 15,723,967 69 middle NDE1/end MYH11 overlap SCZ Sc F 39/37
Sc7292 Dup 16p13.11 15,654,809 – 15,723,967 69 middle NDE1/end MYH11 overlap SCZ + ID Sc M 27/21 confirmed in GWAS
Sc7474 Dup 16p13.11 15,654,809 – 15,723,967 69 middle NDE1/end MYH11 overlap ID Sc M 43/12
Sc7615 Dup 16p13.11 15,654,809 – 15,723,967 69 middle NDE1/end MYH11 overlap SCZ + ID + ASD Sc M 18/14 confirmed in GWAS
Sc11553 Dup 12q24.23 118,741,727 – 118,757,944 16 exons 6 – 9 CIT SCZ Sc F 57/18
Coordinates are according to UCSC build 36 (hg18). Size is minimal CNV size. AAS = Age at sampling; AAO = age at onset; SCZ = schizophrenia; BPD = bipolar disorder; 
MDD = major depressive disorder; Sc = Scottish; Sw = Swedish.
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 CIT Copy Number Variants 
 A duplication in  CIT was detected in 1 female Scottish 
patient with schizophrenia (1/647; 0.15%) but was not de-
tected in the Swedish population-based sample or in any 
control samples from either Scotland or Sweden ( tables 2 
and  4 ). This is unsurprising given the low prevalence and 
de novo nature of this CNV.
 No CNVs were found in  PAFAH1B1 ,  FEZ1 ,  MAP1A 
or  PDE4B in either the Scottish or Swedish samples 
screened in this study.
 Allelic Quantification 
 Allelic quantification was used as a second indepen-
dent method to confirm the 3 duplications detected in the 
MAQ analysis in the Swedish sample set. We selected 15 
SNPs in the  DISC1 duplication, 2 in the  NDE1 and 8 in 
the  NDEL1 duplication ( fig.  1 ; online suppl. table SII). 
The duplications were confirmed in all the individuals.
 Discussion 
 In this population-based CNV study, we detected du-
plications in  DISC1 ,  NDE1  and CIT in the Scottish sample 
set and in  DISC1 ,  NDE1  and  NDEL1 in the Swedish un-
related samples. We found far fewer deletions, detecting 
only 2 in  DISC1  and 1 in  NDE1  in the Scottish samples. 
No deletions were detected in the unrelated population-
based Swedish samples. Duplications may result in ele-
vated mRNA and functional protein which might pro-
duce alterations at the cellular or pathway level. Alterna-
tively, tandem duplications may disrupt the normal gene 
sequence, causing reduced expression of the gene and 
protein, or result in dysfunctional protein expression 
causing haploinsufficiency or loss-of-function. 
 A  DISC1 duplication, encompassing the first exon, was 
found in patients and control individuals of the popula-
tion-based sample, as well as in the related patients and 
a
Sc1900
PD-NOS Sc7615
(SCZ + ID
+ ASD)
Sc1901 Sc1902
Sc1744
DEP
Sc1745
Sc1903
*
*
* *
b
 Fig. 2.  a Microarray analysis of subject Sc1744 using the Affyme-
trix CytoScan 750K array shows a single copy gain of the short arm 
of chromosome 16 at band p13.11. The duplication is approxi-
mately 1.65 Mb in size spanning 14,892,975–16,544,033 (NCBI 
Build 37) and contains a number of genes. The figure was made by 
adding custom tracks to the UCSC Genome Browser (http://ge-
nome.ucsc.edu/cgi-bin/hgGateway).  b Familial pedigree of Sc7615 
(index individual indicated by an arrow). Samples from both par-
ents and all 4 siblings of Sc7615 were screened by microarray. 
Filled symbols represent subjects affected with psychotic disorders 
[schizophrenia (SCZ), psychotic disorder not otherwise specified 
(PD-NOS)] and the horizontal-shaded symbol represents depres-
sive disorder [depression (DEP)]. Other diagnoses include ID and 
ASD. The 16p13.11 duplication (carrier status denoted by an as-
terisk) was found to be maternally inherited and also present in 
two siblings of Sc7615 (Sc1900 and Sc1902). It is interesting to note 
that Sc1744 (the mother of Sc7615) has a strong family history of 
schizophrenia and affective disorders on her side of the family. 
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their unaffected first-degree relatives and appears to be an 
inherited CNV. GWAS and next-generation sequencing 
approaches have not identified a clear association be-
tween  DISC locus variants and schizophrenia, bipolar 
disorders and major depressive disorder, suggesting that 
there are no common variants at this locus to act indepen-
dently to increase the risk of developing these disorders. 
These approaches have however raised the importance of 
rare genomic events such as CNVs conferring risk for ma-
jor psychiatric disorders, but the presence of CNVs in 
 DISC1 and its binding partners has received relatively lit-
tle attention. Duplications in the  DISC1 locus have been 
detected in 3 individuals (1 with schizophrenia and 2 con-
trols)  [113] and a 2-Mb duplication including 7 genes, 
including  DISC1 and  DISC2 has been described in two 
bothers with ASD, attention deficit hyperactivity disor-
der and mild ID  [114] . Interestingly, we detected a dele-
tion encoding intron 3 and 3 alternate exons of  DISC1 in 
a Scottish patient with schizophrenia which was not 
found in any of the control samples. We also detected
a deletion in  TSNAX - DISC1 in a Scottish control sam-
ple. No deletions were observed in the Swedish samples. 
A 2-Mb maternally inherited deletion, encompassing 
 TSNAX ,  DISC1 and  DISC2 , has been identified in a child 
with ASD and has also been shown to be associated with 
structural MRI changes including gliosis and bilateral ce-
rebral white matter changes  [115] . 
 Duplications and deletions of a large region around 
 NDE1 on chromosome 16p13.11 have previously been 
detected in CNV studies for autism and/or ID  [81, 116] 
and schizophrenia  [62, 67, 117] , and described as a poten-
tial risk factor for neuropsychiatric disorders. The (over-
lapping) CNVs probably result from non-allelic homol-
ogous recombination between chromosome 16-specific 
and relatively frequent low copy repeats termed LCR16 
 [116] . The deCODE genetics study examined 4,345 
schizophrenia patients and 35,079 controls from 8 Euro-
pean populations for duplications and deletions at the 
16p13.11 locus and found a threefold excess of duplica-
tions and deletions in schizophrenia cases compared with 
controls with duplications present in 0.30% of cases ver-
sus 0.09% of controls (p = 0.007) and deletions in 0.12% 
of cases and 0.04% of controls (p > 0.05)  [117] . In the 
Scottish population sample in our study, we detected the 
duplication in 5 patients (2 with schizophrenia; 1 with 
schizophrenia and ID; 1 with ID alone and in 1 with 
schizophrenia, ID and ASD) and in no controls (0/352), 
and the deletion was detected in 1 patient with schizo-
phrenia (1/647) and in no controls (0/352). It has been 
shown that approximately 16 protein-coding genes are 
expressed in this 2-Mb duplicated region ( fig. 2 ), 10 of 
which have evidence of brain expression, of which 5 
 (ABCC1, NDE1, NOMO1, NTAN1  and PDXDC1) are 
thought to play a role in brain development  [118] . 
 The duplication in  NDEL1 encompasses the complete 
gene, so potentially may cause an elevated expression of 
NDEL1 mRNA and intact protein. This CNV was only 
found in 1 patient with schizophrenia but not in unaf-
fected individuals, so it could represent a rare but poten-
tially pathogenic variation conferring susceptibility to 
schizophrenia. DNA from the parents of the patient was 
unavailable for typing, so we could not confirm whether 
this is a de novo or inherited variation.  NDEL1 null mice 
are embryonic lethal, but mice with reduced levels of 
NDEL1 show neuronal migration defects resulting in ab-
normal organization of the cerebral cortex  [119, 120] .
At a dosage-sensitive locus with deletion phenotypes, du-
plications have a high likelihood to also produce dis-
ease phenotypes  [121] . While deletions of  PAFAH1B1 
are known to cause lissencephaly with severe brain mal-
formations, individuals with  PAFAH1B1 duplications 
showed mild brain malformations and moderate to se-
vere developmental delay  [122] . Duplication of  NDEL1 
with increased expression of the gene and protein may 
result in a phenotype with ‘milder’ affected brain struc-
ture and/or function such as psychiatric disorders. Inter-
estingly, the observed duplication also encompasses part 
of  MYH10 . This gene encodes myosin heavy chain 10 
non-muscle (myosin IIb) that is abundantly expressed in 
the brain and enriched in the post-synaptic density of 
neurons. It is a molecular motor that binds and contracts 
actin filaments and has been shown to play an essential 
role in axonal outgrowth, dendritic spine motility and 
synaptic function  [123, 124] . Interference with the ex-
pression of this gene or the function of its protein, maybe 
in combination with overexpression of  NDEL1 , possibly 
constitutes an interesting pathological mechanism impli-
cated in schizophrenia. The low frequency of the variant 
nevertheless requires more patients and also more con-
trol individuals to be typed to confirm the relationship of 
this CNV with these disorders. 
 In published genome-wide CNV studies, 4 recurrent 
but rare deletions, at 22q11.2 (VCFS or Di George re-
gion), 1q21.1, 15q11.2 and 15q13.3, showed significant 
association with schizophrenia in large patient-control 
and trio samples  [62, 63] . An elegant translational study 
using human induced pluripotent stem cell-derived neu-
ral progenitor cells, carrying the 15q11.2 deletion, has re-
cently shed light on how this CNV may associate with 
neurodevelopmental disorders  [125] . As a result of hap-
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loinsufficiency of  CYFIP1 , a gene within 15q11.2 that en-
codes a subunit of the WAVE complex which regulates 
cytoskeletal dynamics, the neural progenitors carrying 
this mutation show deficits in adherens junctions and 
apical polarity. By engineering a similar mutation into a 
mouse model, they were able to demonstrate defective 
radial glial cell migration in the developing mouse cortex 
 [125] . Other rare CNVs detected (almost) exclusively in 
patients were described as possible risk factors  [61–67, 
126] , supporting the hypothesis that rare variants with 
relatively high penetrance contribute to the aetiology of 
schizophrenia. In the literature, 5 of the CNVs associating 
with schizophrenia were duplications, raising the poten-
tial pathogenic role duplications have in disease causa-
tion: a de novo duplication at 15q13.1 spanning  APBA2 
 [61] , a duplication at 7q21 including  MAGI2  [65] , a du-
plication at 11p13 encompassing  HIPK3  [127] , a de novo 
duplication at 12q24.23 comprising 8 exons of  CIT and a 
de novo duplication at 14q32 spanning  DICER1  [64] .
 In conclusion, DISC1 and several of its interacting 
partners, which are proposed to be important for normal 
neuronal function, are likely candidates for involvement 
in schizophrenia, schizoaffective disorder and/or bipolar 
disorders. Our findings provide further evidence for in-
volvement of these genes in neuropsychiatric disorders 
and also support the hypothesis of structural variation 
playing an important pathogenic role. Although the vari-
ants we have detected are rare, particularly those that are 
family specific, they are likely to be intractable to GWAS, 
which is of course optimised for the detection of common 
variants across populations. Variants in  DISC1 , which 
were originally implicated in a single Scottish family, have 
only ever reached genome-wide significance levels when 
studied using linkage analysis, consistent with their rare 
frequency and large effect size. Although exceptionally 
rare, they may nonetheless be biologically very informa-
tive. The consequences of these CNVs on transcript and 
protein level should be further investigated. The func-
tional implication of these variants in mental illness and 
the mechanism of disease causation remain elusive, al-
though the potential of investigating this in neuronal cell 
types derived from human induced pluripotent stem cells 
holds much promise. 
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